Quantcast

Latest Prasugrel Stories

2010-09-16 10:31:00

INDIANAPOLIS and TOKYO, Sept. 16 /PRNewswire/ -- In a Phase II study, Acute Coronary Syndrome (ACS) patients on maintenance clopidogrel/aspirin therapy who were switched to prasugrel (Efient® - either 10 mg maintenance dose [MD] or 60 mg loading dose [LD] followed by 10 mg MD) plus aspirin demonstrated a statistically significant greater reduction in Maximal Platelet Aggregation (MPA) after one week when compared to patients who remained on maintenance therapy (MD) with...

2010-09-13 15:24:00

PARSIPPANY, N.J. and INDIANAPOLIS, Sept. 13 /PRNewswire-FirstCall/ -- A study evaluating the level of platelet aggregation achieved after switching from Plavix® (clopidogrel) 75 mg once-daily maintenance dosing plus aspirin to Effient® (prasugrel) 10 mg once-daily maintenance dosing (MD) in patients with acute coronary syndrome (ACS) was published today in the Journal of the American College of Cardiology. In this Phase II study, ACS patients who were...

2010-09-01 07:30:00

SAN DIEGO, Sept. 1 /PRNewswire/ -- Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced today that it has completed its capital financing efforts, the first round of which was announced in the Fall of 2009. The Company raised an additional $7 million in this round and secured a total of $24 million in new...

2010-08-26 07:00:00

CAMBRIDGE, Mass., Aug. 26 /PRNewswire/ -- Sermo (http://www.sermo.com/client), the world's largest online community for physicians, today announced a free Sermo Report titled, "FDA Committee Recommends Approval for Ticagrelor." The report covers physician opinions about the introduction of an investigational oral antiplatelet treatment for acute coronary syndrome (ACS). According to the results, 46% of physicians feel that ticagrelor will likely affect the current standard of care,...

2010-07-27 07:00:00

PARIS, July 27 /PRNewswire-FirstCall/ -- Medco Research Institute(TM), LLC, a wholly owned subsidiary of Medco Health Solutions, Inc. (NYSE: MHS), is sponsoring a study to determine the optimal antiplatelet treatment for patients who are also using a proton pump inhibitor (PPI), a commonly prescribed category of heartburn medications. The study will examine the impact that the PPI, Prevacid® (lansoprazole), has on the effect of two different anti-platelet agents,...

2010-07-19 08:45:00

WALTHAM, Mass., July 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of acute coronary syndrome (ACS), 56 percent of surveyed interventional cardiologists who prescribe Bristol-Myers Squibb/Sanofi-Aventis' Plavix in high doses, consider it to be comparable in efficacy to Daiichi Sankyo/Eli Lilly's recently-launched Effient. The findings in the new Physician & Payer...

2010-06-28 14:00:00

INDIANAPOLIS and PARSIPPANY, N.J., June 28 /PRNewswire-FirstCall/ -- Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in...

2010-05-18 07:30:00

SAN DIEGO, May 18 /PRNewswire/ -- Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow System, the first rapid and easy-to-use diagnostic system for measuring platelet reactivity to multiple antiplatelet agents, announced today that the company has signed a new agreement with Medico's Hirata for distribution of its VerifyNow System in Japan. The VerifyNow System helps physicians assess patients' response to all major antiplatelet therapies such as aspirin,...

2010-04-06 07:30:00

SAN DIEGO, April 6 /PRNewswire/ -- Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow(®) System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS (Gauging Responsiveness with A VerifyNow(®) Assay Impact on Thrombosis And Safety). The trial is specifically designed to...

2010-03-16 10:30:00

ATLANTA, March 16 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced results of a new analysis of the PLATO (A Study of PLATelet Inhibition and Patient Outcomes) study which showed there were fewer deaths in patients with acute coronary syndromes (ACS) who took the investigational oral antiplatelet ticagrelor (BRILINTA(TM)/BRILIQUE(TM)) within seven days prior to having heart bypass surgery (coronary artery bypass graft, CABG) compared to those who took clopidogrel.(1) These...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related